Radiation Oncology
Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.
Recent Discussions
How would you delineate or modify target volumes for stage I NSCLC abutting the chest wall in a thin patient for whom the traditional SBRT PTV margin extends to the skin?
Truncate the PTV. Evidence is Keane et al., PMID 33239160.I am surprised that a PTV margin would extend all the way to the skin surface even for the most peripheral lung lesion. The rib and chest wall diameter for the patient in question must be exceptionally thin (diameter <=5 mm)?
What is the current criteria for sentinel node biopsy over a full axillary lymph node dissection in a patient with breast cancer?
This is a rapidly evolving space.For patients that cN0 with 1-2 or 3 SLN+, ALND can be omitted without gross ECE. Also, the NCCN guidelines have allowed for a similar approach with patients with 2 or fewer nodes on imaging/biopsy. While most patients on AMAROS/Z011 had breast conservation, this appr...
How do you manage pT1-2N0 p16+ tonsil cancer treated with TORS and ipsilateral negative neck dissection but with positive margin?
This would be a very unusual situation, especially if the Q is in reference to the palatine tonsil. A well trained Robotic surgeon generally would not have any problems with performing a Radical tonsillectomy for an early stage tonsil primary. The superior constrictor and the pillars (ant+post) form...
Would you consider PBI plus covering the regional lymph nodes for a LN+ breast cancer in the remnant of the axillary tail?
Was this patient cN0 and had a positive SLN or did they have an ALND? In the setting of a cancer following prophylactic mastectomy (sounds like the original cancer was contralateral) with a positive node, my preference would be to cover chest wall + RNI. I would say that PBI covering regional nodes ...
Do you offer adjuvant radiation therapy for a breast cancer patient with dermatomyositis?
This is an exceptionally important question for clinicians. I'm a little biased as I run an autoimmune Myositis Clinic, but here are my two cents: Paraneoplastic dermatomyositis (DM) is a fairly common occurrence (roughly about 15% of all DM cases, but up to 30-40% in some subtypes, such as adult pa...
Should patients with muscle invasive node negative bladder cancer wishing to have bladder preservation receive chemoRT alone or neoadjuvant chemotherapy followed by chemoRT?
The best evidence that we have does not support neoadjuvant chemotherapy before chemo-RT for bladder cancer. One RTOG trial, admittedly underpowered, and the MRC meta-analysis suggest that, while that benefit may exist for cystectomy, it either doesn't exist or is simply too small to detect for chem...
What role does radiation plan in a pT1a endometrial cancer with two small metastatic foci in the abdomen found during surgery?
I see the limited value of prophylactic RT here and favor systemic treatment only.
How would you treat locoregionally recurrent anal CA?
Surgical resection is standard of care for isolated locoregionally recurrent anal cancer - if the disease is resectable. Resectable disease includes local recurrence in the anal canal and limited nodal disease (i.e. mesorectal, possibly inguinal). Fixed pelvic side wall recurrence (nodal or direct e...
Would you recommend repeat radiation therapy for a painful perineal recurrence in a patient who failed definitive CRT, and recurred again after salvage abdominoperineal resection (APR)?
I think repeat radiation therapy is certainly an option that can be offered to this patient, especially if the interval between treatments is long. MD Anderson reported on a series of 10 patients with anal SCCs treated with reirradiation after definitive CRT (https://www.ncbi.nlm.nih.gov/pubmed/2775...
How are you approaching patients with early-stage NSCLC who progress on neoadjuvant chemo-immunotherapy and are no longer surgical candidates?
This is a good question, and we are seeing it too often these days. This question cites progression as the reason for not proceeding to surgery after neoadjuvant chemo-IO. We are also seeing patient refusal and ineligibility (i.e. N3 disease that didn't respond) as reasons. I think it's very importa...